Salveo

Acute & maintenance treatment of schizophrenia & related psychoses in adult & adolescent (13-17 yr). Monotherapy for the acute & maintenance treatment of manic or mixed episodes associated w/ bipolar I disorder in adults & adolescents (13-17 yr). Adjunct to valproate or lithium in the treatment of manic or mixed episodes associated w/ bipolar I disorder in adults. Prevention of recurrence of manic, mixed or depressive episodes in bipolar I disorder. Acute treatment of depressive episodes associated w/ bipolar I disorder in adults & children (10-17 yr) in combination w/ fluoxetine. Acute treatment of treatment-resistant depression in adult.

Schizophrenia Adult Initially 5-10 mg/day w/ a target dose of 10 mg/day. Adjust dose to increments/decrements of 5 mg/day w/ intervals of not <1 wk. Adolescent 13-17 yr Initially 2.5 or 5 mg w/ a target dose of 10 mg/day. Adjust dose to increments/decrements of 2.5 or 5 mg. Bipolar I disorder (manic or mixed episodes) Adult Monotherapy: 10 or 15 mg/day. Adjust dose to increments/decrements of 5 mg/day w/ intervals of not <24 hr. Adjunctive treatment to lithium or valproate: 10 mg/day. Adolescent 13-17 yr Initially 2.5 or 5 mg/day w/ a target dose of 10 mg/day. Adjust dose to increments/decrements of 2.5 or 5 mg. Preventing recurrence in bipolar I disorder Adult 10 mg/day. Patient in remission Initially 10 mg once daily. Depressive episodes associated w/ bipolar disorder Adult Olanzapine 5 mg & fluoxetine 20 mg once daily in the evening. Childn & adolescent 10-17 yr Olanzapine 2.5 mg & fluoxetine 20 mg once daily in the evening. Treatment resistant depression Adult Olanzapine 5 mg & fluoxetine 20 mg once daily in the evening. Elderly ≥65 yr 5 mg/day. Hepatic &/or renal impairment 5 mg/day.

May be taken with or without food.

Hypersensitivity.

Increased mortality in elderly patients w/ dementia-related psychosis. Neuroleptic malignant syndrome. Wt gain. Patients w/ conditions which may contribute to core body temp elevation. Orthostatic hypotension; patients w/ known CV disease, cerebrovascular disease & conditions which would predispose patients to hypotension. Sudden cardiac death. Co-administration w/ medicines known to increase QTc interval. Hyperglycemia, DM, hyperprolactinemia, hyperlipidemia, leukopenia, neutropenia & agranulocytosis. Patients w/ elevated ALT &/or AST, signs & symptoms of hepatic impairment, preexisting conditions associated w/ limited hepatic functional reserve & treated w/ potentially hepatotoxic medicines; history of seizures or factors which may lower the seizure threshold; prostatic hypertrophy, narrow-angle glaucoma, or history of paralytic ileus or related conditions. Hepatic impairment, or a history of blood dyscrasias, bone marrow depression, or myeloproliferative disease. Discontinue if hepatitis is diagnosed. Consider dose reduction or discontinuation if tardive dyskinesia occurs. Possibility of suicide attempt. Patients at risk of aspiration pneumonia. Potential for cognitive & motor impairment. Pregnancy & lactation. Childn <13 yr. Elderly.

Falls in the elderly; wt gain, elevated prolactin. Accidental injury, fever, back pain, pain in extremity, asthenia, fatigue; postural hypotension, chest pain, tachycardia, HTN; increased appetite, peripheral edema, edema, glycosuria, elevated cholesterol, triglyceride, creatinine & uric acid levels, hyperglycemia; mild transient anticholinergic effects, dyspepsia, vomiting, increased salivation, thirst, nausea, abdominal pain, diarrhea, flatulence; ecchymosis, eosinophilia; increased ALT/AST; extremity pain (other than joint), joint pain, arthralgia, musculoskeletal stiffness, twitching; dizziness, personality disorder, akathisia, somnolence, tremor, insomnia, abnormal gait, hypertonia, articulation impairment, speech disorder, amnesia, paresthesia, depression, apathy, confusion, euphoria, incoordination, extrapyramidal symptoms, sedation, headache, restlessness, agitation, hostility, anxiety, neurosis, hallucinations, abnormal dreams, delusions, emotional lability, manic reaction, schizophrenic reaction; rhinitis, increased cough, pharyngitis, dyspnea, nasopharyngitis, resp tract infection, sinusitis; sweating, acne, dry skin, fungal dermatitis, rash; amblyopia, abnormal vision, blepharitis, corneal lesion; urinary incontinence, UTI, dysmenorrhea, vaginitis, erectile dysfunction in males.

Potentiation of orthostatic hypotension w/ ethanol; diazepam. May enhance the effects of certain antihypertensive agents. Increased clearance w/ carbamazepine. Reduced C_max & AUC w/ activated charcoal. CNS acting drugs & alcohol. Decreased clearance w/ fluvoxamine. May antagonize effects of levodopa & dopamine agonists. May increase clearance w/ omeprazole & rifampicin.

Antipsychotics

N05AH03 - olanzapine ; Belongs to the class of diazepines, oxazepines and thiazepines antipsychotics

Rx